Clinical Trial

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Study acronym: SSc
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-08-01 -> 2028-08-01 2026-08-15
minor Completion pushed: 2026-08-01 -> 2028-08-01 2026-08-15
Trial Details
NCT Number NCT03630211
Lead Sponsor Paul Szabolcs
Conditions Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
Enrollment 8 participants
Start Date 2018-07-31
Primary Completion 2028-08-01 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-14